Skip to content

Comparison of the efficacy of tamsulosin and terazosin in the treatment of voiding dysfunction

Comparing the efficacy of Tamsulosin and Terazosin in treating lower urinary tract obstructive symptoms in women with functional bladder outlet obstruction

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200825048515N85
Enrollment
120
Registered
2025-08-25
Start date
2025-08-23
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional bladder outletobstruction. Disorder of urinary system, unspecified

Interventions

Intervention 1: First Intervention group: Patients in this group receive one tamsulosin capsule at a dose of 0.4 mg at night for 3 months. Intervention 2: Second Intervention group: Patients in this g

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Women with at least 3 months of urinary incontinence Functional urinary incontinence (having an obstructive appearance or high PVR in a uroflowmetry study or a high-pressure, low-flow appearance in a urodynamic study) Age range 18 to 65 years Consent to participate in the study

Exclusion criteria

Exclusion criteria: Having a history of anatomic obstruction or catheter passage during urodynamic study Active urinary tract infection Pregnancy Use of diuretics Heypetension Genitourinary malignancies

Design outcomes

Primary

MeasureTime frame
Flow rate. Timepoint: Before and after intervention. Method of measurement: Based on bladder tape.;Pressure at Qmax. Timepoint: Before and after intervention. Method of measurement: Based on bladder tape.;Urinary dysfunction score. Timepoint: Before and after intervention. Method of measurement: International Prostate Symptom Score (IPSS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Kazemi

Esfahan University of Medical Sciences

Rezakazemi????@gmail.com+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026